Targets › TPOR
2 programs from 2 companies in 3 trials: 3 Phase 2; Hematology, Other; next expected readout Dec 2026.
Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K. In turn, These signaling cascades lead to the proliferation, survival, and differentiation of…. (UniProt, P40238)
Open in Phaseline: the race on TPOR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | herombopag olamine thrombopoietin receptor agonist | TPOR | Phase 2 | Chemotherapy-induced Thrombocytopenia; Herombopag | Dec 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Herombopag Olamine Thrombopoietin receptor (TPO-R) agonist | TPOR | Phase 2 | Thrombocytopenia | Sep 2027 |
Chemotherapy-induced Thrombocytopenia (1) Herombopag (1) Thrombocytopenia (1)
small molecule (2)
Institute of Hematology & Blood Diseases Hospital, China (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.